Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic landscape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using multiple genomic approaches.
the pseudoautosomal region (PAR1) of chromosomes X and Y (P2RY8-CRLF2); rare but recurrent CRLF2 mutations. All three CRLF2-r result in overexpression of CRLF2 mRNA and protein; however, alone they are insufficient to cause overt leukaemia. 5, 7 Interestingly, studies identifying CRLF2-d patients by mRNA and protein expression have shown that some patients do not harbor one of the three known genomic rearrangements. 8 The cause of this overexpression is currently unknown. The incidence of CRLF2-r is high in patients with Down syndrome ALL (DS-ALL) (>50%) and intrachromosomal amplification of chromosome 21
(iAMP21) (25%), 5, 7, 9211 with other established cytogenetic abnormalities rarely associated. However, data indicating whether CRLF2-r is a primary or secondary event are scarce. 12 It is well documented that deletions of genes involved in B-cell differentiation and cell cycle control are recurrent in these patients. 5, [13] [14] [15] Mutations of the Janus kinase family, in particular JAK2, and mutations of IL7R, are also recurrently observed and together result in IL-3 independent growth of mouse BaF3 cells. 11, 16 Recently, mutations affecting other kinase genes have also been reported in CRLF2-d ALL. 4, 17 Both BCR-ABL1-like and CRLF2-d ALL have been associated with poor outcome and increased risk of relapse. 2, 3, 10 Although MRD-directed treatment intensification improves survival, 18 outcome for CRLF2-d ALL remains less favorable than for patients with good risk cytogenetics. Hence, novel therapeutic strategies are required to improve survival and quality of life. In this study, we have explored the clinical and genetic landscape of patients with known CRLF2 rearrangements. The aims of this study were: (1) to identify the clinical and genomic differences that may exist between patients with IGH or P2RY8 driven overexpression of CRLF2; (2) to undertake pathway analysis of whole genome (WGS) and whole exome sequencing (WES) data to highlight additional pathways that may co-operate with rearrangements of CRLF2.
| MATERIALS A ND METHODS

| Patient samples
We identified 172 patients with CRLF2-r ALL by fluorescence in situ hybridisation (FISH) and multiplex ligation-dependent probe amplification (MLPA) from the following trials: UKALL97/99 (n 5 68), UKALL2003 (n 5 75), UKALLXI (n 5 6), and UKALLXII (n 5 26) (Supporting Information Table 1 ). The patients included in this study were identified by screening for CRLF2-r Information Table 2 ).
| Cytogenetics and fluorescence in situ hybridisation
For details on genetic testing, see Supporting Information Figure 1 .
Karyotype data were collected from UK cytogenetics laboratories (Supporting Information Table 1 ). Cytogenetic analysis and FISH were carried out on the same diagnostic patient samples. The involvement of IGH was determined using the LSI IGH Dual Color Break-Apart Rearrangement Probe (Abbott Molecular, Green Oaks, IL). 6, 22 Additional FISH probes used in this study are shown in Supporting Information Table 3 . Five control slides of fixed cells from normal individuals were hybridised with all probe combinations 5 (Supporting Information Table 3 ) to determine the cut-off percentages for false positive results (6 3 3 standard deviations).
A minimum of 100 nuclei were scored by eye for each FISH test by two independent analysts. When combining three or more florophores, capture and scoring was carried out using an automated Olympus BX-61 8-bay stage florescence microscope. Images were analysed using the CytoVision 7.1 SPOT counting system (Leica Microsystems, Gateshead, UK).
| Multiplex ligation-dependent probe amplification
Copy number alterations (CNA) were investigated (n 5 154) by MLPA using the SALSA MLPA kit P335 (MRC Holland, Amsterdam, Netherlands) according to manufacturer's guidelines as previously reported. 
| Low depth paired-end and whole exome sequencing
Sufficient diagnostic DNA was available from 11 CRLF2-r patients (representitive of cohort and all patients have SNP analysis completed), which was prepared for library construction (300-500 bp), flow cell preparation and cluster formation using the Illumina no-PCR library protocol (Illumina Inc, San Diego, CA), and 50 bp reads were performed using the Illumina Genome Analyzer IIx instrument following the manufactures guidelines.
Structural variants were selected as previously reported. 23 Sufficient diagnostic and germ-line DNA from the same 11 patients was prepared for Illumina paired-end sequencing with subsequent exome enrichment using the Agilent SureSelect Human All Exon 50 MB kit (Agilent Technologies LTD, Berkshire, UK). Guidelines for the Illumina Genome Analyzer IIx instrument were followed for flow-cell preparation, cluster generation and paired-end sequencing of 75 bp reads. 23, 24 Whole † These authors contributed equally to this study.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Primers were used to amplify exon 14 of the JAK2 and JAK1 genes only 27 and Sanger sequencing confirmed the presence of the mutation.
As far as we are aware CRLF2 mutations have not been reported in patients with IGH-CRLF2 or P2RY8-CRLF2, therefore screening for these mutations was not carried out.
| Statistical analysis
The distribution of categorical variables was examined using Fisher's exact test. Due to the investigative nature of this analysis, we did not apply stringent multiple comparisons adjustment (all tests were conducted at the 5% significance level). All analyses were performed using Intercooled Stata 14.1 for Windows (Stata Corporation, College Station, TX).
| Pathway analysis
Pathway mapping was performed on a defective gene list identified for each sample. A gene was considered to be defective if: (1) it contained at least one nonsilent mutation, (2) was located at the break point junction of the identified structural variants, and (3) Table 4 ; Figure 1A ). The age distribution was similar to B-ALL overall, with the majority <10 years (71%). 20 Median age (4 y vs. 14 y, P < .001), WBC (25% vs. 43% with WBC >50 3 10 6 /l, P 5 .016) and percentage NCI high risk (38% vs. 77%, P < .001) differed significantly between P2RY8-CRLF2 and IGH-CRLF2, respectively (Supporting Information Table 4 ; Figure 1A ). We confirmed the high frequency of DS-ALL among CRLF2-r ALL (31%, 50/161) (DS status not available for 11 patients), with more DS-ALL patients harboring the P2RY8-CRLF2
fusion (P2RY8-CRLF2, n 5 41 vs. IGH-CRLF2 n 5 9, 35% vs. 20%, respectively, P 5 .087) (Supporting Information Table 4 ; Figure 1B ).
Cytogenetic analysis was successful in 160 CRLF2-r patients. Nor- Information Table 5 ; Figure 1C ).
Copy number alterations (CNA) were detected among patients with CRLF2-r ALL by MLPA (n 5 154) and SNP6.0 arrays (n 5 26) ( Table   1 ; Supporting Information Table 1 and 6-7; Figure 1B) . Deletions of IKZF1, CDKN2A/B, PAX5, and BTG1 were present in 43% (n 5 60), 38%
(n 5 52), 30% (n 5 41), and 14% (n 5 20) of cases, respectively. Deletions of IKZF1 and BTG1 occurred at higher incidences than seen in Bother ALL at 23% and 2%, respectively. 21 Deletions of IKZF1 (71% vs.
33% P < .001) and BTG1 (31% vs. 9%, P 5 .004) were more frequent in IGH-CRLF2 than P2RY8-CRLF2 patients, respectively ( Figure 1B ). There was a lower incidence of PAX5 and IKZF1 deletions in patients with DS-associated CRLF2-r ALL compared to those without DS (18% vs.
35% P < .047 and 23% vs. 53%, P 5 .003, respectively) ( Figure 1C , Supporting Information Table 5 ). In fact, CRLF2-r DS patients were more likely to have none of these deletions (48% vs. 15%, P < .001), with 89% (39/44) having fewer than three gene deletions.
Other recurrent CNA observed from SNP6.0 arrays included: the histone cluster at 6p22.2 (n 5 7), VPREB1 (n 5 6), ADD3 (n 5 5), BTLA (n 5 4), SLX4IP (n 5 3), SERP2 and TSC22D1 (n 5 3), and PBX3 (n 5 2).
Publically available SNP6.0 data 32 showed these deletions to be present in other ALL subtypes: ADD3, n 5 9 (4.69%), SLX4IP, n 5 9 (4.69%), and TSC22D1 (7/55, 13%), and PBX3 (16/56, 29%), with no difference in the prevalence between DS and non-DS CRLF2-r ALL. IGH-CRLF2
patients had a higher incidence of ADD3 deletions (46% vs. 13%, IGH vs. P2RY8, P 5 .008) (Supporting Information Table 6 ; Figure 1B ).
| A novel fusion between USP9X and DDX3X
An interstitial deletion of chromosome sub-band Xp11.4, fusing USP9X
to DDX3X (Supporting Information Figure 3A ), was observed in 2/26 cases by SNP6.0 arrays and 7/24 cases by FISH, including one DS patient, giving an incidence of 19% (Supporting Information Figure 3B ).
No cases were identified among the publically available SNP6.0 data.
32
FISH revealed that the fusion was present in both minor and major clones (8-91% of nuclei) in both male (n 5 4) and female patients (n 5 5). All male patients had either an additional copy of normal chromosome X or derived X involved in the CRLF2-r. It was identified in patients with both IGH and P2RY8 involvement (4 vs. 5, respectively).
Real-time PCR confirmed that the fusion was in-frame and was expressed at the mRNA level (Supporting Information Figure 3C ).
Sanger sequencing verified fusion of USP9X exon 31 to exon 2 of DDX3X (Supporting Information Figure 3D ). The DNA breakpoint sequence from three patients consistently fell within intron 31 of In the majority of patients, at least half of the mutations were at variant allele frequency (VAF) higher than 30%; only one patient (#11706) had a higher number of mutations at a VAF of <20%. Recurrent mutations were identified in CACNA1D, IKZF1, JAK2, IL7RA, NRAS, and USH2A
(n 5 2 each). Ten patients had missense or nonsense point mutations in genes with protein kinase functions (Table 1) , with six patients harboring either a mutation or CNA in two or more kinase genes.
Targeted screening for JAK2 (n 5 75) and JAK1 (n 5 36) mutations identified an incidence of 35% and 14%, respectively. There was no difference in the number of JAK1 or JAK2 mutations between IGH-and P2RY8-CRLF2 (17% vs. 19%, P 5 .46) or DS and non-DS patients (JAK2 Ex14, 44% vs. 35%, P 5 .613; JAK1 Ex14, 17% vs. 11%, P 5 1; Supporting Information Table 5 ; Figure 1B ,C). Due to selective screening of only exon 14 in the majority of patients, these numbers may represent an underestimate of the true incidence of JAK1 and JAK2 mutations in CRLF2-r ALL. 
| DISCUSSION
In this study investigating the genomic landscape of CRLF2-r ALL, we have confirmed the high incidence of CRLF2-r in DS-ALL, demonstrated its co-existence with other primary chromosomal rearrangements and enrichment of specific chromosomal gains and deletions of IKZF1, BTG1, ADD3, SERP2, TSC22D1, SLX4IP, and PBX3. There were significant differences in CNA profiles between P2RY8-CRLF2 and IGH-CRLF2 patients with an increased incidence of IKZF1, BTG1, and ADD3
deletions and a higher age at diagnosis being observed in the latter.
These disparities correlate with reported differences in outcome, where for example older age and IKZF1 status drive the inferior prognosis observed in adult IGH-CRLF2. 14 A fifth of CRLF2-r patients harbor a primary chromosomal abnormality with all but one being P2RY8-CRLF2, suggesting a co-operating role for CRLF2 deregulation. Interestingly, the sole patient with IGH-CRLF2 and a primary abnormality had the BCR-ABL1 fusion in a separate clone. 22 Collectively, these data do not imply that IGH and P2RY8 are driving distinct subgroups but rather that CRLF2-d may play a dual role as both a primary and co-operating driver in ALL, with the latter being more prominent among P2RY8-CRLF2 patients. This model is akin the BCR-ABL1 fusion, which although predominatly a primary driver, has also been reported as a secondary abnormality 22, 33 . Independent pathway analysis of the aberration profile of IGH-CRLF2 and P2RY8-CRLF2 patients found enrichment of all top ten pathways in the P2RY8-CRLF2 patients and only a subset of pathways in IGH-CRLF2 patients. Previous studies have reported the involvement of MAPK signaling in CRLF2-r ALL. 34 This pathway was not significantly enriched in our IGH-CRLF2 patients;
however, this observation was based on only four patients and thus requires further validation. WES identified a frequency of 20 mutations per patient, similar to iAMP21-ALL, 35 but higher than other subgroups, 23, [36] [37] [38] . The high VAF of kinase mutations suggested that they were clonal and were likely acquired early in disease development.
Mutations in ERBB4, TTBK1, and STK38L occurred within the catalytic domain with potential for constitutive activation. These mutations may activate STAT5 (ERBB4), deregulate alternate pathways including, For the first time, we have implicated a role for USP9X and DDX3X
in CRLF2-r ALL. This USP9X-DDX3X fusion removes the ubiquitin carboxyl-terminal hydrolase domain of USP9X, the promoter of DDX3X, multiple regulatory elements, MIR7641-2 and non-coding RNAs. The involvement of USP9X and DDX3X in cancer is known [39] [40] [41] [42] [43] [44] [45] and another translocation involving USP9X has been reported in a BCR-ABL1-like ALL patient without CRLF2-r. 4 In keeping with the emerging functions of USP9X, its overexpression has been reported in B-ALL, suggesting an oncogenic role. 46 Knockdown of USP9X sensitises both prednisolone sensitive and resistant cell lines to glucocorticoid (GC)-induced apoptosis, suggesting that reduced levels of USP9X may sensitise them to prednisolone treatment. 46 With the success of targeted approaches using tyrosine kinase inhibitors (TKI) in BCR-ABL1-positive disease, there is clear rational to apply similar targeted approaches to other ALL subtypes. CRLF2-r activate targetable pathways, including JAK-STAT, PI3K, and MAPK signaling, and many groups are now assessing the efficacy of inhibitors to these pathways. The first inhibitor to be tested in CRLF2-r ALL was the JAK1/2 inhibitor, Ruxolitinb. 47 While this study showed a response in vivo, greater effect was observed in JAK-activated, non-CRLF2-r ALL.
Evidence of resistance to type I inhibitors in model systems of B-ALL is already driving the development of type II JAK inhibitors. 48 Targeting of mulitple pathways was an approach taken by Suryani et al, (2015) in assessing the JAK inhibitor, AZD1480, alone and in combination with the MEK inhibitor, Selumetinib. 49 While this study showed a strong anti-leukaemic effect in vitro, only modest effects were seen in vivo, an important consideration for future preclinical testing, which highlights the need to identify other common targets to provide further options for more patients. In addition to JAK-STAT, we have identified several deregulated pathways in CRLF2-r ALL, for example, focal adhesion signaling, one which has not previously been implicated in this subtype of ALL and was enriched in patients with both IGH-and P2RY8-CRLF2
ALL.
Mutations within genes controlling cell adhesion would seem to be and migration in various cancers. 51, 52 In a recent study, the presence of the Ikaros isoform 6 (IK6), IKZF1 haploinsuficiency or mutations in BCR-ABL1-positive disease have been shown to increase expression of adhesion molecules and increased transcription of FAK, rendering these cells insensitive to tyrosine kinase inhibition. 53 The application of inhibitors to FAK in patients with BCR-ABL1-positive ALL resulted in the same abrogation of adhesion and self renewal programmes. 54 Interestingly, all 11 patients with sequencing data either showed mutation/ CNA of IKZF1 or a mutation within a focal adhesion gene. Our data along with emerging literature in leukaemia highlight a role for the focal adhesion pathway in CRLF2-r ALL.
In summary, we show clear clinical and genomic differences between patients with IGH-and P2RY8-CRLF2. We describe these rearrangements in the presence of other established cytogenetic abnormalities, suggesting a secondary role for CRLF2-r in some patients, akin to BCR-ABL1 positive disease. However, due to low patient numbers, we were unable to ascertain any impact of P2RY8-CRLF2 on the prognosis of these patients. This co-occurrence needs to be further assessed in a larger patient cohort. The treatment of patients across four independent trails precluded meaningful survival analysis between patients IGHand P2RY8-CRLF2. It is clear from our data that CRLF2-r ALL is hetero- 
